RxDoctor Payments Data

Sarah Baker, MD

Dermatology · Bossier City, LANPI 1730335753

Payments from drug & device makers

$7,209in general payments, 2019–2025

Across 374 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Johnson & Johnson$722
  • Galderma Laboratories, L.p.$421
  • Sanofi$402
  • Lilly USA, LLC$282
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$2313%
  • Food & beverage$6,59091%
  • Education$3885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,209 in reported general payments places this provider in the 55th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$389,125
Medicare patients
1,228
Services billed
7,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$343,917
Dupixent SyringeDupilumab79$300,428
OtezlaApremilast49$241,919
Dupixent PenDupilumab61$232,640
Taltz AutoinjectorIxekizumab25$166,719
OpzeluraRuxolitinib Phosphate11$22,179
Fluorouracil103$7,549
Doxycycline Monohydrate231$5,936
Acitretin12$5,228
Ketoconazole244$3,759
Clobetasol Propionate109$3,677
Metronidazole63$2,697
Fluocinonide68$2,585
Hydroxychloroquine Sulfate72$2,130
Betamethasone Dipropionate38$2,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$91$241,91949 claims
Incyte CorporationOpzelura$97$22,17911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →